All News

CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

d Jack Cush, MD

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Read Article
Pills.men_.jpg

Rheumatoid Arthritis Nonadherence is Multifactorial

d Jack Cush, MD

The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging.  A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

d Jack Cush, MD

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
Mortality of Cryoglogulinemia has declined between 1999 and 2018 freom 0.4 deaths per million to 0.19. Cryo found in 39% of HCV(2009–2013) down to 26% (2014–2018). Prevalence and deaths dropped witn introduction of HCV antiviral Rx https://t.co/h9rL1ftI0n

Links:

Dr. John Cush RheumNow ( View Tweet)

Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/QUbsIQtcRa https://t.co/zAMUp99ecg

Links:

Dr. John Cush RheumNow ( View Tweet)
Olumiant (baricitinib) studies in Lupus halted by Lilly due to mixed results in phase 3 trials. While the BRAVE-1 study showed 4-mg BARI meeting primary endpoint at 52 weeks; the Brave-II failed to do same & failed key secondary endpoints https://t.co/XBmo15UCYl

Links:

Dr. John Cush RheumNow ( View Tweet)

Lupus international cohort study of 1460 HCQ pts showed that SLE flares were increased with dose reduction (aHRs 1.20;CI 1.04 to 1.38) and HCQ discontinuation (aHR 1.56; 1.31 to 1.86), higher with low educational levels after HCQ D/C https://t.co/fO4fBtrFYo

Links:

Dr. John Cush RheumNow ( View Tweet)

Fatigue in Early RA registry - study of n = 1236 pts w/ Dz duration 11 mos. The prevalence rates of fatigue was 44% and severe fatigue 19% and was stable over 3 yrs. Greater fatigue in women, high pain, mental Dz, function; BUT NOT SJC or ESR https://t.co/hEgPbsAqYZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Taiwan study of 12,786 pre-dialysis advanced CKD patients with gout shows that use of febuxostat or allopurinol was assoc w/ a reduced sepsis/infection risk - most w/ FEB (HR, 0.68; 0.52–0.87), but no signif difference in MACE or CVA https://t.co/zp7JLwzah8

Links:

Dr. John Cush RheumNow ( View Tweet)

Join Dr. Ronan Kavanagh for an incredible STEP Session at #RNL2022, where he will discuss The Jazz of Rheumatology. Register today! https://t.co/hMzdpN327q https://t.co/uHYC9VV1kp

Links:

Dr. John Cush RheumNow ( View Tweet)
Round up of last week's QD Clinics: -Steroid Weaning -Diagnosing Neuropsychiatric Lupus - Not the Same Ol’ Lecture - Your Next Follow-up Visit is When? QD Clinic is sponsored by RheumNow Live https://t.co/9U1wcbIMs4 https://t.co/HjyyGtbe4r

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank case control study of 15 871 pts with Gout and COVID. Gout associated with diagnosis of COVID-19 (OR 1·20; CI 1·11–1·29) but not with risk of COVID-19-related death in the cohort of patients diagnosed with COVID-19 (1·20, 0·96–1·51). https://t.co/dN5YnIqhzD

Links:

Dr. John Cush RheumNow ( View Tweet)

Should we use colchicine in COVID-19? Mainly mixed results; not likely effective in sick hospitalized patients but may have utility in early infections https://t.co/wecWjSIbEG

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: NEJM study of ~2000 persons showed that prior PCR proven SARS-CoV-2 infection was effective at preventing Symptomatic Reinfection against alpha variant (90.2%), beta ( 85.7%), delta (92%), but not omicron variant (56%). https://t.co/UkvDUH6alK

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Retrospective study of 179 antiphospholipid syndr pts, looked at noncriteria findings- their presence incr relapse rates (59% vs 34%;p=0.018) triple positivity & need for Rx. (cytopenias, APS nephropathy, livedo, CNS, Libman Sachs endocarditis) https://t.co/i7UItlDcHd

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Women Heroes in Rheum: - Barbara Ansell - JIA - Nanna Svartz-SSZ - Gertrude Elion - Nobel Prize for allopurinol, AZA - Tsai-Fan Yu - gout Rx - Mary Betty Stevens - lupus/vasculitis - Marian Ropes - 1st F ARA president - Fionula Brennan-TNFi & more https://t.co/0kxrXo5fr3 https://t.co/QfCDxkfYRi

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Approximately 61% of patients with rheumatoid arthritis or psoriatic arthritis who use methotrexate report side effects following weekly dosing, including fatigue and nausea, according to data published in Rheumatology and Therapy https://t.co/65OMw9A96h

Links:

Dr. John Cush RheumNow ( View Tweet)

Data from 2 phase III studies of psoriatic arthritis using tofacitinib, adalimumab shows that a significant meaningful clinical response is achieved in 29-53 days -- why then are we not making go vs no-go decisions with modern biologics at 6-8 weeks? https://t.co/F56P9c3Rb5

Links:

Dr. John Cush RheumNow ( View Tweet)

CARRA Registry looked at TNFi use in JIA and found a nearly 3 fold increased risk of psoriasis. 8225 pts w/ 3.9 yrs of F/U. 54% recv TNFi; the aHR of new onset of psoriasis after TNFi exposure was 2.93 (2.15 to 3.98). MTX had lower risk (HR 0.45) https://t.co/Z6qvlS26M9

Links:

Dr. John Cush RheumNow ( View Tweet)

Osteoarthritis Initiative study looked at Hand OA. Among 3588 participants, 41% had hand OA by xray and 12.4 % by Sxs. Over 4 yrs, 27.3 % showed Xray OA progression. More in women (DIPs)>men (MCPs), but less in blacks https://t.co/WRZYcL7zFH

Links:

Dr. John Cush RheumNow ( View Tweet)

×